Basic information Description Indication Mechanism of Action Toxicity Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Neuronal Signaling >  Adrenergic Receptor agonists >  Indacaterol

Indacaterol

Basic information Description Indication Mechanism of Action Toxicity Safety Supplier Related

Indacaterol Basic information

Product Name:
Indacaterol
Synonyms:
  • Indacaterol
  • 5-[(1R)-2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one
  • Indacaterol-d3
  • CS-272
  • (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylaMino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, Maleate salt
  • Arcapta
  • 5-[2-(5,6-Diethyl-2,3-dihydro-1H-inden-2-ylaMino)-(1R)-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one
  • (R)-5-(2-(5,6-Diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-
CAS:
312753-06-3
MF:
C24H28N2O3
MW:
392.49
EINECS:
691-091-1
Product Categories:
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Agonist
  • Amines
  • Aromatics
  • Inhibitors
  • Heterocycles
Mol File:
312753-06-3.mol
More
Less

Indacaterol Chemical Properties

Melting point:
>165°C (dec.)
Boiling point:
660.3±55.0 °C(Predicted)
Density 
1.27
storage temp. 
-20°C Freezer, Under inert atmosphere
solubility 
DMSO (Slightly), Methanol (Slightly)
pka
8.68±0.20(Predicted)
form 
Solid
color 
Off-White to Light Yellow
InChI
InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1
InChIKey
QZZUEBNBZAPZLX-QFIPXVFZSA-N
SMILES
N1C2=C(C([C@@H](O)CNC3CC4=C(C3)C=C(CC)C(CC)=C4)=CC=C2O)C=CC1=O
More
Less

Indacaterol Usage And Synthesis

Description

Indacaterol is a new, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist that was developed by Novartis. The drug is used in managing and controlling chronic obstructive pulmonary disease (COPD) and asthma. The European Medicines Agency (EMA) approved indacaterol as a drug in 2009 under the Onbrez trade name while in the United States the Food and Drug Administration approved it under the trade name Arcapta in 2011. The drug is manufactured as its maleate salt form. Also, indacaterol is a chiral molecule; however, only the pure R-enantiomer is distributed.

Indication

Indacaterol is used in the maintenance of airflow obstruction in individuals with COPD for the long term, including emphysema and chronic bronchitis.

Mechanism of Action

By stimulating the adrenergic beta-2-receptors in the airways’ smooth muscles, indacaterol is able to cause relaxation, thus augmenting the diameter of the airways that are normally constricted in COPD and asthma. Because of its high affinity to the lipid draft domains in the membrane of the airways, it is long acting, therefore it slowly detaches from the receptors. It is rapid acting due to its high intrinsic characteristic.

Toxicity

In case of an overdose of indacaterol, the expected signs and symptoms include excessive beta-adrenergic stimulation, hypotension, hypertension, nervousness, fatigue, hyperglycaemia, insomnia, and metabolic acidosis.

Description

Inhaled β2 adrenoceptor agonists are effective in the management of asthma and COPD, primarily through their bronchodilating properties. These drugs induce bronchodilation by causing direct relaxation of airway smooth muscle through activation of adenylate cyclase, which in turn increases intracellular cAMP levels. Indacaterol is the newest β2 agonist to reach the market. It is an ultra-long-acting agent with a duration of action suitable for once-a-day dosing. Indacaterol is supplied as an aerosol formulation of its maleate salt and is administered via a dry powder inhaler device. It is specifically approved for once-daily maintenance treatment of airflow obstruction in adult patients with COPD. In preclinical models, indacaterol is close to a full agonist at the human b2 adrenoceptor (Emax = 73 ± 1% of isoprenaline′s maximal effect, pEC50 = 8.06 ±0.02) while salmeterol displays only partial efficacy (38 ±1%). The functional selectivity profile of indacaterol over β1 human adrenoceptors is similar to that of formoterol, whereas its β3 adrenoceptor selectivity profile is similar to that of formoterol and salbutamol.

Originator

Novartis (United Kingdom)

Uses

Indacaterol is a β-adrenoreceptor agonists for treatment of asthma and bronchodilator treatment for patients with chronic obstructive pulmonary diseases.

Definition

ChEBI: A monohydroxyquinoline that consists of 5-[(1R)-2-amino-1-hydroxyethyl]-8-hydroxyquinolin-2-one having a 5,6-diethylindan-2-yl group attached to the amino function. Used as the maleate salt for treatment of chronic obstructive pulmonary di ease.

brand name

Onbrez Breezhaler

Side effects

The most commonly reported adverse events associated with indacaterol treatment were nasopharyngitis, upper respiratory tract infection, and headache and cough following inhalation. Adverse events were mild or moderate in most cases, and became less frequent with continued treatment.

Synthesis

The chemical synthesis of indacaterol begins with a-chlorination of 5-acetyl-8-benzyloxy-2-quinolone with benzyltrimethylammonium dichloro-iodate. The resultant chloroketone is reduced with borane in tetrahydrofuran in the presence of the chiral boron catalyst R-tetrahydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo[1,2c][ 1,3,2]oxazaborole to produce the corresponding chlorohydrin intermediate in high enantiomeric excess. The chlorohydrin intermediate is cyclized to the corresponding epoxide by treatment with potassium carbonate, the epoxide is condensed with 5,6-diethylindan-2-amine, and the benzyl protecting group is removed by hydrogenolysis to produce indacaterol. The 5,6-diethylindan-2-amine intermediate is derived from 1,2-diethylbenzene via Friedel-Crafts acylation with 3-chloropropionyl chloride, cyclization of the resultant 3-chloro- 1-(3,4-diethylphenyl)-1-propanone by means of concentrated sulfuric acid to 5,6-diethylindan-1-one, oximation with butyl nitrite, and reduction of the oxime to an amine via treatment with hydrogen over palladium- carbon.

IndacaterolSupplier

Jinan Billion Pharmaceutical Technology Co., Ltd Gold
Tel
+86-15589952515 +86-15589952515
Email
80912934@qq.com
Jinan zhongdaoanran chemical Co;Ltd Gold
Tel
18678233466 18678233466
Email
122574856@qq.com
Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
JinYan Chemicals(ShangHai) Co.,Ltd.
Tel
13817811078
Email
sales@jingyan-chemical.com